Tag - Zylö Therapeutics

Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED

Ziad2022-11-25T13:59:44-05:00Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a one-year $263,000 Small Business Innovation Research (SBIR) grant to: (i) optimize a formulation of sildenafil (generic name of Viagra) loaded into Zylö’s proprietary silica-based Z-pods and (ii) demonstrate that the topical formulation is comparable in efficacy to orally administered sildenafil in a mouse model of erectile dysfunction [ED], with aged mice. The grant is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases,...

Zylö Receives $600,000 NIH Phase I Grant to Develop a Novel Therapeutic to Treat Onychomycosis (Nail Fungus)

Ziad2022-11-25T13:59:44-05:00Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a two-year $600,000 Small Business Innovation Research (SBIR) grant to generate a final formulation of Zylö’s proprietary nitric oxide-releasing topical drug candidate optimized for the treatment of onychomycosis. The grant is sponsored by the National Institute of Allergy and Infectious Diseases, a division of the NIH. Read more >>

Nine Upstate organizations named as 2022 InnoVision Awards finalists

Ziad2022-11-25T13:59:45-05:00Nine Upstate organizations were named as 2022 InnoVision Awards finalists, the organization’s board of directors announced Aug. 2. The awards honor South Carolina individuals and organizations for impactful innovations under development in the state within the last 18 months. Awards will be given in six categories. One of The nominees: Technology Integration-Zylo Therapeutics Inc. – Greenville. All finalists will be recognized during the virtual InnoVision 2022 Meet the Finalists Series sponsored by South Carolina Research Authority. Read more >>

Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.

Ziad2022-11-25T13:59:45-05:00Silo Pharma, Inc., a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study. Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in...

Zylö Therapeutics Closes $5.225 Million Series B Financing

Ziad2022-11-25T13:59:45-05:00Zylö Therapeutics Inc., dedicated to developing a transformational drug-delivery platform, announced that it has raised $5.225 million in its Series B financing. The Series B round was led by a consortium of seasoned investors, spearheaded by James Cordes, who recently joined the Zylö board of directors. Other key participants were: (i) VentureSouth (which led the Series A round) which invested more than $1.3 million in the Series B round; (ii) the New York Angels, an angel group that has played...

Startup: Zylö Therapeutics — Small company, big idea

Ziad2022-11-25T13:59:58-05:00Scott Pancoast believes he can put Greenville on the map with his company’s product, and he’s ready to take it to the world. Zylö Therapeutics is a technology startup that uses a silica powder, called Z-pods — very similar in consistency to talcum powder — to be the vehicle of transport for everything from pain relievers to pesticides. The Z-pods have far-reaching medical applications, as they’ve shown promise in promoting hair growth, treating acne, relieving pain, helping with erectile dysfunction...

Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics

Ziad2022-11-25T14:00:10-05:00Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has entered into an agreement with Zylö Therapeutics to license its novel cannabinoid therapeutic, HT-005 for lupus patients, back to Zylö. Read more >>

Zylö Therapeutics receives $300K investment from SC Launch

Ziad2022-11-25T14:00:10-05:00SC Launch Inc., South Carolina Research Authority (SCRA’s) investment affiliate, announced Dec. 7 it has invested $300,000 in Zylö Therapeutics Inc., a medical research business in Greenville. Read more >>

SC Launch, Inc. Announces Third Investment in Zylö Therapeutics

Ziad2022-11-25T14:00:10-05:00South Carolina Research Authority (SCRA’s) investment affiliate, SC Launch, Inc. has made its third investment into Zylö Therapeutics, Inc. This $300,000 investment will help the company continue providing therapeutic topical solutions. Read more >>

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

Ziad2022-11-25T14:00:11-05:00Silo Pharma, Inc. a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod® transdermal technology. Read more >>